<!DOCTYPE html>
<html>
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <link rel="stylesheet" type="text/css" href="css/style-manual.css">
    <link rel="stylesheet" href="https://www.w3schools.com/w3css/4/w3.css">
    <script src="js/script.js"></script>
</head>
<body>
<!--Methebac-------------------------------------------------------->
<div class="bodyDiv" id="idMethebac">
    <div class="w3-container w3-center w3-animate-left">
        <h2 class="mango">Methebac</h2>
    </div>
<b>Product Orientation & Presentation:</b><br>
 <table class="table1">
 <tr>
    <th>Brand Name:</th>
    <th>Methebac</th>
  </tr>

  <tr>
 
    <td>Generic & Strength:</td>
	<td>Methenamine Hippurate 1gm</td>
    
  </tr>
  
  <tr>
    <td>Dosage Form:</td>
    <td>Tablet</td>
    
  </tr>
	 
  <tr>
    <td>Therapeutic Class:</td>
	<td>Anti-Septic</td>
    
  </tr>

  <tr>
    <td>Sub Therapeutic class: </td>
	<td></td>
    
    </tr>
		
  
  <tr>
    <td>Commercial Pack:</td>
	<td> 
	5×6's
	</td>
    
  </tr>
	 
   <tr>
    <td>Price (TP):</td>
    <td> 25 tk/Tab
        </td>
	
   </tr>	
	 
   <tr>
 
    <td>Flavour </td>
    <td>.</td>
	 
  </tr>
  
  <tr>
 
    <td>Indication:</td>
    <td>
	Recurrent UTIs
	</td>
  </tr>
  
  <tr>
<td>Pregnancy: 
</td>
<td>
</td>
</tr>

<tr>
<td>Lactation: 
</td>
<td>
</td>
</tr>

  
  <tr>
    <td>Children: </td>
    <td>
</td>
  </tr>
  
   <tr>
    <td>Brand Name Justification: </td>
    <td>   </td>
  </tr>
  
  <tr>
<td>Brand Slogan: 
</td>
<td>Non-antibiotic approach to treat recurrent UTIS 
</td>
</tr>

 <tr>
<td>Dosage & Administration: 
</td>
<td>
&#x2022; 1 g twice daily
</td>
</tr>

<tr>
<td>Key Selling Points: 
</td>
<td>
&#x2022; Act as a urinary antiseptic with antibacterial and even antifungal activity.<br>
&#x2022; Offers a successful treatment option in recurrent UTIs<br>
&#x2022; Provides continuous antibacterial activity (24 hours) with twice daily doses<br>
&#x2022; Ensures avoiding repeated courses of antibiotics.

</td>
</tr>

<tr>
<td>Target Doctor: 
</td>
<td>
&#x2022; Gyaenocologists<br>
&#x2022; Nephrologists ban<br>
&#x2022; Urologists<br>
&#x2022; Medicine Specialists
</td>
</tr>

<tr>
<td>Side effects: 
</td>
<td>
&#x2022; 

</td>
</tr>

<tr>
<td colspan="4">
<table class="table2">
<thead>
<tr>
<th></th>
<th>Mode of action:</th>
<th></th>
</tr>
</thead>
<thead>
<tr>
<th>
</th>
<th>Methenamine Hippurate</th>
<th>
</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dissociates into</td>
<td></td>
</tr>
<tr>
<td>↓</td>
<td></td>
<td>↓</td>
</tr>
<tr>
<td>Methenamine</td>
<td></td>
<td>Hippuric acid</td>
</tr>
<tr>
<td>↓</td>
<td></td>
<td>↓</td>
</tr>
<tr>
<td>Breaks into formaldehyde & ammonia</td>
<td></td>
<td>Bacteriostatic activity</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td></td>
<td>
*Bactericidal activity<br>
*Bacteriostatic activity</td>
<td></td>
</tr>
<tr>
<td colspan="4">

</td>
</tr>
</tbody>
</table>

</td>
</tr>
</table>
<br><br>
	
	





Direct Competitor:<br>
Brand Name<br>
Hipomax<br>
Company Name<br>
Nuvista<br>


Market situation including activities of leading competitors<br>
According to IMS MAT 20'22 anti-septic in UTIS drug market size is around 35 crore and the total generic market size of Methenamine Hippurate is 1.28 Crore. So, we have to give more focus on Methebac & promote to all Gynaecologists, Nephrologists and Urologists and the doctors who are prescribing Nitrofurantoin and Nuvista's Hipomax.<br>
Value (Cr.)1.28 Crore<br>
Growth %999<br>

Indirect Competitor: Nitrofurantoin: Market Size: 33.63 Cr. Growth: -17%<br>
Company Name  Brand Name  Value (Cr.)  Growth%<br>
Incepta   NINTOIN  20.41  4<br> 
UMACTIN  Unimed Unihealth  5.35  -7.04<br>
OFURAN  Pacific  3.63  -19%<br>
NITROFUR  ACI 3.19  -.68<br>
UROCURE  Square  2.58  8<br><br>


Objective for 4th QTR 2022<br>
• Establish Methebac as the drug of choice in recurrent UTIs in the specialty of
Gynae, Nephro, Uro and Medicine Sp.<br>
• Each MPI must ensure adequate shelving and promote the to target doctors.<br>
• Ensure at least 1 Rx/day from 1 doctor<br>
Model Detail Talk (Card lit)<br>
Actions to be taken in 4th QTR 2022<br>
1. Every RI, AI & MPI must memorize the Lit. & should ensure detailing to their selected doctors.<br>
2. Arrange scientific seminar at Gynae, Nephrology and Urology Department.<br>
3. Every MPI must ensure 1 Rx per day.<br><br>

Dear Sir/Madam:<br>
In your daily practice, you are getting many recurrent UTIS patients. The burden of
recurrent UTIS has the societal aspects including clinical and economic burden of illness as well as the personal burden including social and psychological effects which having a negative impact on quality of life.<br>
Dear Sir/Madam,<br>
to treat or prevent recurrent UTIS,Navana Pharma introduces,Methebac, a preparation of Methenamine Hippurate.A novel, non-antibiotic approach to treat recurrent UTIS.<br><br>


Every women experiences UTI at least once in life. Almost 30% among them are
getting recurrence within 6 months, 3% among them with third-time infection.<br>
Acts as a urinary antiseptic with antibacterial and even antifungal activity.<br>
Methebac is better than Nitrofurantoin<br>
Responders Rate of Methenamine 75%<br>
Responders Rate of Nitrofurantion 43%<br>
A Bangladeshi trial confirms<br>
66%<br>
E. coll becomes resistant to
Nitrofurantoin<br>

Offers a successful treatment option in recurrent UTIS<br>
Sir/Madam, Prescribe Methenamine confidently,<br>
Act as a urinary antiseptic with antibacterial and even antifungal activity.<br>
Offers a successful treatment option in recurrent UTIS<br>
Provides continuous antibacterial activity (24 hours) with twice daily doses<br>
Ensures avoiding repeated courses of antibiotics<br>
Methebac is approved by USFDA, UK-MHRA, TGA &
BNF included.<br>
Widely prescribed in developed countries (USA, UK, Australia,
Japan).<br>


Sir/Madam,<br>
Considering all these benefits, may I expect 3 Rx for your next available patien Thank you Sir/Madam. Methebac is available at x, y, z Pharmacy.<br><br>



Frequently Asked Questions (FAQ)<br>
1. What is the percentage of UTIS caused by E.coli?<br>
Ans: 90%<br>
2. Responder rate of Methenamine in UTIS?<br>
Ans: 75%<br>
3. What is the dosage guideline of Methebac in adults?<br>
Ans: 1 g, 3 times daily.<br>
4. What is the percentage of E.coli that becomes resistant to Nitrofurantoin?<br>
Ans: 66%<br><br>


Methebac<br>
Methenamine Hippurate USP 1 g Tablet<br>
A novel, non-antibiotic approach<br>
to treat recurrent UTIS<br>
Doctor & MPI Talk<br>
Dear Sir/Madam, আসসালামু আলাইকুম, আপনি আপনার প্রতিদিনের practice এ অনেক UTI এর রোগী পেয়ে
থাকেন। এদের মধ্যে অনেক রোগীরই দ্বিতীয়বার এমনকি তৃতীয়বার পর্যন্ত ও infection হতে পারে। এ জন্য বার বার
antibiotic repeat করতে হয়, এর ফলে antibiotics resistant হয়ে যেতে পারে।
MPI: Dear Sir/Madam,<br>
non-antibiotic approach<br>
Doctor: আপনি ঠিকই বলেছেন, আমি প্রতিনিয়তই UTIS এর রোগী পাই, যাদের অনেকেই দ্বিতীয় বার infection
নিয়ে আসে।<br>
Navana Pharma<br>
Tablet Methebac, totally
bactericidal & bacteriostatic activity<br>
Dear Sir/Madam, a unique mood of action show Methenamine hippurate
dissociated হয়ে Methenamine এবং hippuric acid এ পরিণত হয়। এই Methenamine ভেঙ্গে
formaldehyde এবং ammonia তৈরী করে, যা পর্যায়ক্রমে bactericidal এবং bacteriostatic activity
show করে। Hippuric acid ও bacteriostatic activity show করে। এই unique properties এর জন্য
recurrent UTIS হবার সম্ভাবনা কমে যায়।<br>
Dear Sir/Madam, Methebac is better than Nitrofurantoin in terms of responders
rate, Nitrofurantoin responders rate only 43% & Methenamine responders rate
75%. Moreover, 66% E.coli becomes resistant to commonly prescribed
Nitrofurantoin trial- confirmat 2362 I So, We can say Methebac
is better than Nitrofurantoin. Methebac is approved by USFDA, UK-MHRA, TGA &
BNF included. Widely prescribed in developed countries (USA, UK, Australia,
Japan).<br>
• Act as a urinary antiseptic with antibacterial and even antifungal activity.<br>
• Offers a successful treatment option in recurrent UTIs<br>
• Provides continuous antibacterial activity (24 hours) with twice daily doses<br>
• Ensures avoiding repeated courses of antibiotics.<br>
Considering these benefits, may I expect 5 Rx daily in favour of Methebac.<br>
</div>   
<footer>
    <p>© 2024 Md. Nurullah. All rights reserved.</p>
</footer>
<center><div class="ovalEnd">The End-Methebac</div></center><!--End Line---->
</body>
</html>